Posted by Michael Wonder on 26 Jun 2023
Soliris recommended for approval in the EU by CHMP for children and adolescents with refractory generalised myasthenia gravis
26 June 2023 - The first in class C5 inhibitor reduced disease severity and symptoms with sustained improvements over 26 weeks in Phase III clinical trial.
Soliris (eculizumab) has been recommended for marketing authorisation in the European Union for expanded use to include the treatment of refractory generalised myasthenia gravis in children and adolescents aged six to 17 years who are anti-acetylcholine receptor antibody positive.
